L1 ANSWER 6 OF 10 WPIX COPYRIGHT 2007 THE THOMSON CORP on STN
ACCESSION NUMBER: 2000-183843 [17] WPIX
DOC. NO. CPI: C2000-057836 [17]
TITLE: New 3-(4-amino-5-ethyl-2-pyrimidinyl)-1-(2-fluorobenzyl)-
1H-pyrazolo(3,4-b)pyridine useful as a vasodilator,
platelet aggregation inhibitor and hypotensive e.g. for
treating cardiovascular diseases
DERWENT CLASS: B02
INVENTOR: ALONSO-ALIJA C; DEMBOWSKY K; FEURER A; FUERSTNER C;
FUERSTNER-ROBYR C; HUETTER J; PERZBORN E; STAHL E; STASCH
J; STRAUB A
PATENT ASSIGNEE: (FARB-C) BAYER AG
COUNTRY COUNT: 85

PATENT INFO ABBR.:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
DE 19834045	A1	20000203	(200017)*	DE	12[0]	
<--						
WO 2000006567	A1	20000210	(200017)	DE		
<--						
AU 9951604	A	20000221	(200029)	EN		
EP 1104421	A1	20010606	(200133)	DE		
JP 2002521481	W	20020716	(200261)	JA	34	

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
DE 19834045 A1		DE 1998-19834045	19980729
AU 9951604 A		AU 1999-51604	19990716
EP 1104421 A1		EP 1999-936550	19990716
WO 2000006567 A1		***WO 1999-EP5071	19990716***
EP 1104421 A1		WO 1999-EP5071	19990716
JP 2002521481 W		WO 1999-EP5071	19990716
JP 2002521481 W		JP 2000-562369	19990716

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 9951604 A	Based on	WO 2000006567 A
EP 1104421 A1	Based on	WO 2000006567 A
JP 2002521481 W	Based on	WO 2000006567 A

PRIORITY APPLN. INFO: DE 1998-19834045 19980729
AN 2000-183843 [17] WPIX

AB DE 19834045 A1 UPAB: 20060116
NOVELTY - 3-(4-Amino-5-ethyl-2-pyrimidinyl)-1-(2-fluorobenzyl)-1H-
pyrazolo(3,4-b)pyridine (I) is new.
DETAILED DESCRIPTION - 3-(4-Amino-5-ethyl-2-pyrimidinyl)-1-(2-
fluorobenzyl)-1H-pyrazolo(3,4-b)pyridine of formula (I) is new.
INDEPENDENT CLAIMS are also included for:
(1) medicaments containing (I) and optionally an organic nitrate or
nitric oxide (NO) donor or a compound that inhibits degradation of cyclic
guanosine monophosphate (cGMP);
(2) the preparation of (I);
(3) 1-(2-fluorobenzyl)-1H-pyrazolo(3,4-b)pyridine-3-carboxamidine
of formula (II); and
(4) the preparation of (II).
ACTIVITY - Anticoagulant; hypotensive; nootropic; neuroprotective;
anxiolytic; antidepressant; analgesic; cardiant; antianginal;
antiarrhythmic; vasotropic; antiarteriosclerotic; uropathic;
gynecological; tranquilizer; antimigraine.
MECHANISM OF ACTION - Soluble guanylate cyclase stimulator. Pig
aorta endothelial cells incubated for 10 minutes in stimulation buffer (no
details given) and then for 10 minutes in the presence of 1 muM (I) showed
a more than 10-fold increase in cyclic guanosine monophosphate (cGMP)
level.
USE - (I) is useful a vasodilator, platelet aggregation inhibitor
and hypotensive agent for increasing coronary blood flow by direct
stimulation of soluble guanylate cyclase and increase of intracellular
cyclic guanosine monophosphate (cGMP) levels. It is also useful for
treating hypertension, cardiac insufficiency, angina, peripheral and
cardiac vascular disease, arrhythmia, thromboembolic and ischemic diseases
(e.g. myocardial infarction and stroke), peripheral circulatory disorders,
restenosis, arteriosclerosis, urogenital diseases (e.g. prostatic
hyperplasia), erectile dysfunction, female sexual dysfunction and
incontinence, as well as diseases of the central nervous system caused by
disorders nitric oxide/cGMP system, e.g. cognitive dysfunction,
Alzheimer's disease, anxiety, stress, depression, sexual dysfunction,
sleep disorders, eating disorders, migraine and pain.

Member(0002)
ABEQ WO 2000006567 A1 UPAB 20060116

NOVELTY - 3-(4-Amino-5-ethyl-2-pyrimidinyl)-1-(2-fluorobenzyl)-1H-
pyrazolo(3,4-b)pyridine (I) is new.
DETAILED DESCRIPTION - 3-(4-Amino-5-ethyl-2-pyrimidinyl)-1-(2-
fluorobenzyl)-1H-pyrazolo(3,4-b)pyridine of formula (I) is new.
INDEPENDENT CLAIMS are also included for:
(1) medicaments containing (I) and optionally an organic nitrate or
nitric oxide (NO) donor or a compound that inhibits degradation of cyclic
guanosine monophosphate (cGMP);
(2) the preparation of (I);
(3) 1-(2-fluorobenzyl)-1H-pyrazolo(3,4-b)pyridine-3-carboxamidine
of formula (II); and
(4) the preparation of (II).
ACTIVITY - Anticoagulant; hypotensive; nootropic; neuroprotective;
anxiolytic; antidepressant; analgesic; cardiant; antianginal;
antiarrhythmic; vasotropic; antiarteriosclerotic; uropathic;
gynecological; tranquilizer; antimigraine.
MECHANISM OF ACTION - Soluble guanylate cyclase stimulator. Pig
aorta endothelial cells incubated for 10 minutes in stimulation buffer (no
details given) and then for 10 minutes in the presence of 1 muM (I) showed
a more than 10-fold increase in cyclic guanosine monophosphate (cGMP)
level.
USE - (I) is useful a vasodilator, platelet aggregation inhibitor
and hypotensive agent for increasing coronary blood flow by direct
stimulation of soluble guanylate cyclase and increase of intracellular
cyclic guanosine monophosphate (cGMP) levels. It is also useful for
treating hypertension, cardiac insufficiency, angina, peripheral and
cardiac vascular disease, arrhythmia, thromboembolic and ischemic diseases
(e.g. myocardial infarction and stroke), peripheral circulatory disorders,
restenosis, arteriosclerosis, urogenital diseases (e.g. prostatic
hyperplasia), erectile dysfunction, female sexual dysfunction and
incontinence, as well as diseases of the central nervous system caused by
disorders nitric oxide/cGMP system, e.g. cognitive dysfunction,
Alzheimer's disease, anxiety, stress, depression, sexual dysfunction,
sleep disorders, eating disorders, migraine and pain.

Member(0004)
ABEQ EP 1104421 A1 UPAB 20060116
NOVELTY - 3-(4-Amino-5-ethyl-2-pyrimidinyl)-1-(2-fluorobenzyl)-1H-

pyrazolo(3,4-b)pyridine (I) is new.

DETAILED DESCRIPTION - 3-(4-Amino-5-ethyl-2-pyrimidinyl)-1-(2-fluorobenzyl)-1H-pyrazolo(3,4-b)pyridine of formula (I) is new.

INDEPENDENT CLAIMS are also included for:

(1) medicaments containing (I) and optionally an organic nitrate or nitric oxide (NO) donor or a compound that inhibits degradation of cyclic guanosine monophosphate (cGMP);

(2) the preparation of (I);

(3) 1-(2-fluorobenzyl)-1H-pyrazolo(3,4-b)pyridine-3-carboxamidine of formula (II); and

(4) the preparation of (II).

ACTIVITY - Anticoagulant; hypotensive; nootropic; neuroprotective; anxiolytic; antidepressant; analgesic; cardiant; antianginal; antiarrhythmic; vasotropic; antiarteriosclerotic; uropathic; gynecological; tranquilizer; antimigraine.

MECHANISM OF ACTION - Soluble guanylate cyclase stimulator. Pig aorta endothelial cells incubated for 10 minutes in stimulation buffer (no details given) and then for 10 minutes in the presence of 1 muM (I) showed a more than 10-fold increase in cyclic guanosine monophosphate (cGMP) level.

USE - (I) is useful a vasodilator, platelet aggregation inhibitor and hypotensive agent for increasing coronary blood flow by direct stimulation of soluble guanylate cyclase and increase of intracellular cyclic guanosine monophosphate (cGMP) levels. It is also useful for treating hypertension, cardiac insufficiency, angina, peripheral and cardiac vascular disease, arrhythmia, thromboembolic and ischemic diseases (e.g. myocardial infarction and stroke), peripheral circulatory disorders, restenosis, arteriosclerosis, urogenital diseases (e.g. prostatic hyperplasia), erectile dysfunction, female sexual dysfunction and incontinence, as well as diseases of the central nervous system caused by disorders nitric oxide/cGMP system, e.g. cognitive dysfunction, Alzheimer's disease, anxiety, stress, depression, sexual dysfunction, sleep disorders, eating disorders, migraine and pain.